Prostate cancer and breast cancer are the most common malignancies in the western world. Androgen receptor (AR) and PTEN both have been well documented to have important roles in prostate carcinogenesis. In contrast, AR and PTEN in breast carcinogenesis have not been well studied. Furthermore, the crosstalk and connection between those two pathways remain unclear. Increased AR expression in prostate cancers, combined with decreased PTEN expression, portends a poor clinical outcome. Paradoxically, both high AR and high PTEN levels, detected by immunohistochemistry, in primary breast carcinomas have been associated with better disease-free survival. Here, we performed in silico analysis of publicly available microarray data sets from prostate or breast carcinomas. We found an inverse correlation between AR and PTEN transcript expression in prostate cancer tissues in contrast to the positive correlation in breast cancer. These data led us to hypothesize that AR may directly affect PTEN transcriptional regulation in prostate and breast cancer cells. Here, we show for the first time that AR inhibits PTEN transcription in prostate cancer cells, whereas AR upregulates PTEN transcription in breast cancer cells, which mechanistically explains both the immunohistochemical PTEN-AR expressional data noted in clinical trials and in our in silico analysis of the transcriptomes of breast and prostate cancers. In addition, we have fine-mapped the AR-binding motif within the PTEN promoter. Here we show that, in patients with Cowden syndrome, an inherited cancer syndrome caused by germline mutations scattered throughout PTEN, point variants affecting the 3 0 end of the AR-binding motif result in abrogation of androgen-mediated transcriptional regulation of PTEN expression. We may speculate that the differential AR effect on PTEN may begin to explain organ-specific and perhaps sex-specific neoplasia predisposition in Cowden syndrome, as well as why only a fraction of women with germline PTEN mutations develop breast cancer, depending on the androgen steroid milieu and levels.
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Introduction
Androgen receptor (AR) belongs to the nuclear receptor superfamily and can function as a transcription factor. Presence of ligand, such as dihydrotestosterone (DHT), induces AR phosphorylation and a conformational change, which results in its nuclear translocation and target gene regulation. Androgen and the functional status of AR are important mediators of prostate cancer progression. Amplification of AR is often observed in advanced prostate cancer (Visakorpi et al., 1995) . Teleologically, this provides prostate cancer cells with a potential survival advantage under low androgen levels after androgen ablative treatment and, therefore, leads to progression to hormone-refractory disease. In females, AR regulates the development of the female reproductive tract, bone, kidneys and muscle. The ovaries stop making androgens after menopause, at which time a large percentage of female breast cancers are diagnosed. At least one report suggested that AR mediates an inhibitory effect on breast cancer cell proliferation through induction of apoptosis (Birrell et al., 1995) . In contrast to worse outcome in prostate cancer patients, expression of AR, detected by immunohistochemistry, has been found to be significantly associated with better survival among breast cancer patients (Agoff et al., 2003; Ogawa et al., 2008) . Accordingly, androgens such as fluoxymesterone have been used as second-line hormonal therapy for advanced breast cancers, whereas most prostate cancer patients are treated with androgen antagonists to inhibit AR.
The tumor suppressor gene PTEN, located on chromosome 10q23, is one of the most frequently altered genes in a broad variety of human cancers (Eng, 2003) . Through its phospholipid 3-phosphatase activity, PTEN negatively regulates the (PI3 K)/Akt pathway, which is involved in cell proliferation, migration and apoptosis. Both monoallelic and biallelic deletions of PTEN occur in prostate cancer cell lines and non-cultured human prostate tumor specimens (Wang et al., 1998; Bedolla et al., 2007; Sircar et al., 2009) . Germline and somatic alterations of PTEN also have important roles in breast cancers . Germline PTEN mutations were first identified in Cowden syndrome (CS), which confers a high risk of breast, thyroid and other cancers (Liaw et al., 1997) . In fact, female CS patients with germline PTEN mutations have a significantly higher risk of breast cancers than those without identifiable mutations (Marsh et al., 1998) . Approximately, 85% of classic CS patients and 10% of Cowden-like (CSL) patients have germline PTEN mutations, with the most characterized ones being intragenic. Although proven pathogenic mutations in the promoter have been described (Zhou et al., 2003b; Teresi et al., 2007) , there are many more 5 0 -UTR variations that are not well understood.
In both heritable and sporadic cancers, when PTEN is absent or dysfunctional, Akt phosphorylation and activity are significantly increased in vitro and in vivo (Stambolic et al., 1998; Zhou et al., 2003a; Agrawal et al., 2005) . PTEN inhibits phosphorylation of Akt, which, in turn, stimulates AR phosphorylation and activity in prostate cancers (Wen et al., 2000) . In addition, PTEN also directly interacts with the AR DNA-binding domain/Hinge domain and inhibits AR nuclear translocation and AR-mediated transcriptional activity in prostate cancer cells (Lin et al., 2004) . However, it is still unclear whether the converse, AR regulates PTEN, occurs, and if so, whether the AR-PTEN crosstalk is similar or different in prostate versus breast cancer models. Therefore, we sought to determine if and how AR regulates PTEN, addressing the hypothesis that AR directly regulates PTEN at the transcriptional level through an AR response element (ARE) in both breast and prostate cancer cells and in the Cowden-inherited cancer syndrome.
Results

AR-mediated PTEN transcriptional repression in prostate cancer cells
Amplification of AR and loss of PTEN protein expression during development and progression of prostate cancer suggest potential regulation between AR and PTEN at several possible levels, including transcriptional, translational or post-translational level. To begin to explore which of these mechanisms are involved, we investigated the correlation between increased AR and decreased PTEN using publicly available whole genome transcriptome data sets utilizing prostate carcinomas derived from patients. A search through the Gene Expression Omnibus was performed for prostate cancer samples and a total of seven data sets (345 patients) were identified for meta-analysis. The forest plot showed that the transcripts of AR and PTEN in prostate carcinomas are clearly inversely correlated (correlation coefficient À0.291, with the upper limit being À0.171 and the lower limit being À0.401; Figure 1a ). Therefore, on the basis of these observations, we hypothesized that the decreased PTEN expression observed clinically might be a direct result of AR transcriptional regulation.
Before investigating whether AR regulates PTEN, we exposed the androgen-dependent prostate cancer cell line LNCaP and its androgen-independent subclone C4-2 cells to DHT, an AR ligand, or Casodex (also called bicalutamide), an AR antagonist used clinically to treat androgen-dependent prostate cancer. We transfected the relevant cells with a reporter plasmid containing a luciferase reporter, driven by a promoter comprising six copies of AREs. For both cell lines, the luciferase assay demonstrated that DHT stimulated AR transcriptional activity, whereas Casodex significantly decreased its transcriptional activity (Figure 1b) .
To elucidate whether AR directly regulates PTEN expression in prostate cancer cells, AR-positive LNCaP and C4-2 cells, and AR-negative PC3 cells were transfected with PTEN-promoter luciferase reporter plasmids and treated with DHT or Casodex. Reporter constructs included a full-length (À1344 to À1) and truncated (À1344 to À1001) PTEN promoter (Teresi et al., 2008) . Both PTEN promoters, the full-length as well as the À1344 to À1001 segments, could be inhibited by DHT and activated by Casodex in AR-positive LNCaP and C4-2 cells (Figure 1c ). In contrast, neither PTEN promoter constructs responded to DHT or Casodex in PC3 cells (Figure 1c , lower panel), indicating that the androgen-associated PTEN promoter activity is AR-dependent. We also observed this androgen effect in LAPC4 cells (Supplementary Figure 1) . To further confirm the AR-mediated androgen effect on PTEN promoter, we knocked down AR by transfecting cells with anti-AR siRNA. AR knockdown increased PTEN promoter activity by 2.5-fold, but DHT or Casodex had no further effect on PTEN promoter activity (Figure 1d , Supplementary Figure 2) . Therefore, our data here suggest that AR, which represses PTEN transcription, mediates androgen-induced transcriptional inhibition of PTEN in prostate cancer cells.
Next, we used the chromatin immunoprecipitation (ChIP) assay to investigate whether AR directly binds to the PTEN promoter in prostate cancer cells in order to mediate the negative regulation. AR pulldown from ChIP assays was quantified by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and normalized to the 3% input. Our data showed that AR interacts with the PTEN promoter in AR-positive CWR22rv1 and LAPC4, but not in AR-negative DU145 cells, and that DHT significantly promotes this interaction in the AR-positive cells (Figure 1e , upper panel). We also extracted mRNA from these three cell lines to further confirm whether DHT represses endogenous PTEN transcription in prostate cancer cells. qRT-PCR data showed that this DHT-induced AR binding repressed endogenous PTEN transcription in both CWR22rv1 and LAPC4 cells, but not in DU145 cells Growth rates of the cells were assessed by the MTT assay, as previously described . Note that DHT stimulated C4-2 cell proliferation, whereas the growth of MDA-MB-453 cells was inhibited by DHT. Neither DU145 nor MDA-MB-231 cells responded to DHT treatment. Figure 7) . The proliferation of AR-negative MDA-MB-231 cells was not affected by DHT (Figure 2e ). Clinical correlative data have shown that lower expression of AR or lower PTEN protein levels are correlated with breast cancer development and progression (Perren et al., 1999; Ogawa et al., 2008) . To further elucidate a mechanism for this correlative observation, we again turned to whole transcriptome data sets from breast carcinomas, which were available publicly. A search through the Gene Expression Omnibus was performed for those breast cancer samples, the expression arrays of which were analyzed on Affymetrix HGU133Plus2.0 platform (GPL570). A total of 16 data sets (1180 patients) met our selection criteria and each individual data set was reviewed for meta-analysis. Forest plot showed a positive correlation between AR and PTEN transcript expression in breast cancer tissues (correlation coefficient þ 0.122, with the upper limit being 0.179 and the lower limit being 0.064; Figure 3a) . From these data, we surmised that AR might directly effect PTEN expression at the transcriptional level.
To determine whether AR regulates PTEN in breast cancer cells, we transfected MDA-MB-453 cells with PTEN-luciferase reporter. In contrast to what we observed in prostate cancer cells, DHT increased the transcriptional activities of the PTEN promoters in the breast cancer cells (Figure 3b ). ChIP assay quantified by qRT-PCR showed the interaction between AR and the PTEN promoter, and DHT significantly conferred this interaction in MDA-MB-453 cells (Figure 3c , left panel). This DHT exposure promoted AR binding that was associated with increased endogenous PTEN transcript levels in breast cancer cells, which is the converse of that observed in prostate cancer cells (Figure 3c , right panel). We also showed that DHT alone stabilized the AR, accompanied by subsequent increase in endogenous PTEN transcript and protein levels (Figure 3d , Supplementary Figure 8 ). The AR knockdown, which promoted breast cancer cell growth, not only decreased PTEN transcript and protein levels, but also abolished DHT-stimulated PTEN expression (Figure 3d , Supplementary Figure 8) .
Previous reports have shown that p53 regulates PTEN transcription through the broad À1190 to À1157 promoter region (Stambolic et al., 2001; Tang and Eng, 2006) . To determine whether p53 is directly involved in AR-regulated PTEN expression, we used MDA-MB-453 cells expressing mutant p53 without transcriptional activity, compared with p53-wild-type (WT) MCF-7 cells (Figure 3e ). DHT exposure resulted in similar PTEN transcriptional responses in both cell lines, suggesting that AR-regulated PTEN expression is independent of p53 ( Figure 3e, right panel) . Our results here suggest that AR mediates the effect of the androgen by stimulating both PTEN transcription and protein expression in breast cancer cells.
Identification of the AR-binding element in the PTEN promoter So far, our data show that AR can regulate both the À1344 to À1 and À1344 to À1001 regions of the PTEN promoter in prostate and breast cancer cells, suggesting that the ARE is located within the À1344 to À1001 region (Figures 1c and 3b) . To identify the potential AR-binding site on the PTEN promoter, we used the ChIP assay to interrogate sequential overlapping of 100-bp segments of the PTEN promoter between À1344 and À1001. The ChIP assay data were quantified by qRT-PCR, which showed that AR had a high affinity to the À1244 to À1044 region of the promoter in CWR22rv1, LAPC4 and MDA-MB-453 cells (Figure 4a, Supplementary Figure 9 ). Our data suggest that this AR binding might also affect histone methylation of the PTEN promoter (Supplementary Figure 10) . Deletion of the À1225 to À1172 region of the PTEN promoter resulted in loss of response to DHT in both the CWR22rv1 and MDA-MB-453 lines (Figure 4b ), indicating that the ARE is located within the À1225 to À1172 region. Taking this observation (Figure 4b ) together with the ChIP assay on AR in LAPC4 cells (Supplementary Figure 9) , we may even be able to postulate that the ARE rests at the À1194 to À1172 region.
To precisely identify the ARE in this (more conservative) À1225 to À1172 region, we made a series of luciferase reporters, driven by PTEN promoters containing partially overlapping substitutions (Figure 4c , Sub A to G). C4-2 and MDA-MB-453 cells were transfected with each of the mutant PTEN promoter plasmids or the WT as control (Figure 4d ). The mutant promoters Sub E, F and G (substitution from À1177 to À1152) showed significantly decreased baseline transcriptional activity in both cell lines, indicating the importance of this region for PTEN transcription (Figure 4d ). In C4-2 prostate cancer cells, DHT decreased PTEN promoter activity for the control and each of the substituted promoters, except for Sub D (À1189 to À1178) and Sub E (À1177 to À1166) promoter regions, which demonstrate the least response to DHT (Figure 4d, left panel) . The mean relative response ratios comparing DHT exposure with control were 0.9 for Sub D and 1.1 for Sub E, compared with 0.6-0.75 for WT and the Subs A-C constructs ( Figure 4d , left 2 panels). From this experiment, the maximal ARE region would span from À1189 to À1166. In MDA-MB-453 cells, the control and most mutant PTEN promoters responded to DHT by increasing transcriptional activity, except for the promoter constructs Sub D (À1189 to À1178) and possibly Sub E (Figure 4d , right panels). It is important to note that Sub C overlaps with Sub D from À1189 to À1186, yet the response of Sub C to DHT is no different from the WT construct (Figure 4d, right panels) . Although the baseAndrogen differentially regulates PTEN in two cancer types Y Wang et al line transcriptional activity of Sub F and Sub G were depressed, both showed a response to DHT in both cell lines (Figures 4c and d) . Sub E and Sub F share À1168 to À1166 region. Thus, combining the above data, a minimal ARE region within the PTEN promoter is À1184 to À1170 (AGTGCAGCTGCA GGC) (Figure 4c ).
Germline alterations within and around the ARE in patients with CS and CSL Although point mutations and variants can be found in the PTEN promoter in CS and CSL patients, small deletions appear to be less common. Nevertheless, large germline deletions and rearrangements involving the promoter including this ARE region are found in 10% p53 transcriptional activity was assayed using a dual luciferase assay. MCF-7 and MDA-MB-453 cells were co-transfected with PTEN promoter reporter plasmids and Renilla-Luc control. Cells were treated, as indicated, for 48 h before PTEN promoter activity was assayed using a dual luciferase assay.
Androgen differentially regulates PTEN in two cancer types Y Wang et al of CS/CSL patients (Zhou et al., 2003b) . However, we wondered whether a more limited germline deletion or point variant involving the ARE region exists. We scanned 2399 CS/CSL patient samples and found 299 (7.7%) patients who have germline variants in the PTEN promoter within the À1344 to À745 region (Figure 5a ). Among those 299 patients, we found 11 patients with mutations/small deletions between À1225 and À1140 of the PTEN promoter, within or just at the ARE region that we identified above. There were two patients with a germline heterozygous 12-bp deletion (À1199 del 12) in the PTEN promoter (Figure 5b) . The 3 0 end of this deletion lies 2 bp upstream of the 5 0 end of the ARE. We also found three patients with germline heterozygous À1170 C4T point mutation located closest to the 3 0 end of the ARE region identified above (Figure 5b ). We modeled these two mutants into our PTEN-promoter reporter constructs and used the luciferase assay to determine its transcriptional activity in response to androgen. The À1199 del 12 mutant PTEN promoter showed decreased baseline transcriptional activity compared with that of the control (Figure 5d ). These results are consistent with the decreased PTEN protein levels in the patients' samples by western blot (data not shown). Interestingly, in C4-2 cells, this del-12 mutant did show a weakened response to DHT (normalized activity ratio for ÀDHT/ þ DHT ¼ 1.67 for the WT construct, compared with 1.25 for the del 12 construct; Figure 4d , left panel). In contrast, DHT response in the del 12 mutant did not differ from the WT construct in the MDA-MB-453 cells. Of note, the À1170 C4T PTEN promoter was unable to respond to DHT in both C4-2 (P ¼ 0.141) and MDA-MB-453 cells (P ¼ 0.298; Figure 5d ). In addition, the À1170 C4T mutant showed decreased baseline transcriptional activity in C4-2 cell (Figure 5d , left panel), whereas this baseline transcriptional activity did not change in MDA-MB-453 cells (Figure 5d , right panel).
Discussion
There exist ample data showing that the PTEN/Akt pathway can regulate AR phosphorylation, activity and degradation (Manin et al., 2002; Nan et al., 2003; Lin et al., 2004; Ghosh et al., 2005; Wang et al., 2007; Mikhailova et al., 2008) . However, it was not known whether AR could regulate PTEN. Thus, we set out to address the hypothesis that the feedback loop can be closed, such that AR can regulate PTEN. Here, we have shown that androgen regulates PTEN transcriptional expression, through AR, in both prostate and breast cancer cells, but in opposite directions ( Figure 6 ). In prostate cancer cells, AR binds the PTEN promoter as a repressor, inhibiting its transcription. In contrast, AR stimulates PTEN gene expression as an activator in breast cancer cells. Therefore, it mechanistically explains both the differential correlations between the expression of AR and PTEN that we found in prostate and breast cancer tissues by in silico analysis of microarray expressional data and the observations between PTEN and AR protein levels in the clinical trial setting. In addition, we identified the ARE in the PTEN promoter, Androgen differentially regulates PTEN in two cancer types Y Wang et al through which AR regulates PTEN expression in both prostate and breast cancer cells. Our data indicate a new mechanism that steroid nuclear receptors can directly regulate the PTEN cell-signaling pathway in cancer cells. It also provides a novel mechanism, whereby androgen/AR mediates opposing effects in prostate and breast cancers. It has been well documented that increased AR expression correlates with prostate cancer progression (Visakorpi et al., 1995) . Other reports also show that immunohistochemical loss of PTEN protein expression is associated with poorer clinical outcome for prostate cancer patients (Whang et al., 1998; Bedolla et al., 2007) . In contrast, clinical reports associate decreased AR expression, by immunohistochemistry, with breast cancer progression (Agoff et al., 2003; Ogawa et al., 2008) . Independently, PTEN-null status by immunohistochemistry in breast cancers is associated with poorer outcome and with a higher frequency of metastatic disease (Perren et al., 1999) . Our in silico analysis using 1180 patients' breast cancer samples from 16 data sets confirm this, and our functional work provides, for the first time, plausible mechanisms for these clinical correlative observations. Breast cancer is often diagnosed after menopause when the ovaries stop producing androgens. Our data suggest that changes in the androgenic hormonal milieu may modulate PTEN expression and lead to hormone-related neoplasias, such as breast and prostate cancers of AR regulation. More importantly, we found that androgen/AR regulate PTEN expression in opposite directions in prostate compared with breast cancer cells. As a nuclear receptor, AR binds AREs in the promoters of its target genes functioning as a transcription activator or repressor, depending on its cofactors. The formation of a preinitiation complex with AR coactivators, such as steroid receptor coactivator-1 (SRC1), transcriptional intermediary factor 2 (TIF2) and amplified in breast cancer 1 (AIB1), results in the activation of target gene transcription (Anzick et al., 1997; Chen et al., 1997; . At the same time, AR can also downregulate target genes by recruiting corepressors, such as the well-known nuclear receptor corepressor (NCoR1) and silencing mediator of retinoid and thyroid hormone receptor (SMRT/NCoR2; Dotzlaw et al., 2002; Hodgson et al., 2005) . The distinct effect of AR on PTEN expression may be due to the different, perhaps organ-specific, AR cofactors in prostate and breast cells. An investigation beyond the scope of this study is required to demonstrate the detailed mechanism of how AR differentially regulates PTEN expression in the two types of cancers. AR regulatory regions are not only located within proximal promoters, but also in distant promoter regions. Further investigation to identify additional AR regulatory regions in the PTEN promoter/enhancer region(s) is critical to fully understand the mechanism of AR-regulated PTEN expression in tumorigenesis.
Examining the germline mutations, variants and deletions in CS/CSL individuals reveal 299 (7.7%) patients who have germline variants in the PTEN promoter within the À1344 to À745 region (Figure 5a ). Combined with our mutagenesis assay, we identified an ARE at À1185 to À1170 of the PTEN promoter (Figure 5b ). The À1170 germline variant found in three CS/CSL patients mutates the nucleotide closest to the 3 0 endof the ARE, yet, PTEN transcriptional response to DHT is completely abrogated in both prostate and breast cancer cells, suggesting that the last base pair of the ARE in the PTEN promoter is critical for AR regulation in both prostate and breast cancer cell lines. The del 12-germline mutation adjacent to the ARE not surprisingly results in decreased promoter activity in both breast and prostate cancer cells. Moreover, this deletion partially weakened the promoter response to DHT only in prostate cancer cell line, but not in breast cancer cells. Combined with the decrease in the PTEN protein levels of the patients, the data suggest that the À1199 to À1188 region in the PTEN promoter is more important in baseline transcription instead of ARinduced regulation. This observation also confirms that the 5 0 extent of the ARE, as identified, is accurate. We noted that the overall frequency for variants or small deletions residing squarely in the midst of the ARE À1185 to À1170 region is very low (essentially 3 of 299) among CS/CSL patients, although it should be noted that PTEN is a tumor suppressor gene and germline mutations are scattered throughout the gene. There are two alternative interpretations. The first, and more plausible, is that the ARE has a vital role during human development; therefore, specific mutations within the ARE might result in in utero lethality. The second possibility is that the ARE region is functionally unimportant.
To date, little is known about the regulation of PTEN expression, especially that mediated by steroid hormone receptors. Here, we demonstrate a novel mechanism in which androgen transcriptionally regulates PTEN, in opposing directions, in the most common cancers in men and women, respectively. These data help elucidate the mechanism behind the clinical observation of the inverse correlation of AR and PTEN expression in prostate cancer progression, compared with the relationships of AR and PTEN expression in breast cancer prognosis. We have found that this crosstalk between male sex steroid hormones and the PTEN pathway is tissue-dependent with different androgen-mediated PTEN responses between breast and prostate neoplasias. It is possible that the differential AR effect on PTEN may explain organ-specific and perhaps sexspecific neoplasia predisposition in CS. This phenomenon may begin to provide a testable hypothesis to explain why only a fraction of women with germline PTEN mutations develop breast cancer, depending on the androgen steroid milieu and levels.
Materials and methods
Meta-analysis of the correlation coefficient between AR and PTEN All analyses were performed in R version 2.10.0 (Ihaka and Gentleman, 1996) . A search through the Gene Expression Omnibus was performed for the words 'prostate cancer, patient samples' and 'breast cancer, patient samples'. Only those studies that contained more than 10 patients were included. We specifically excluded cultured cancer cells and the patients who received previous/ on-going treatment. For prostate cancer studies, we also excluded the samples that contain less than 50% tumor content. For breast cancer studies, results were limited to the Affymetrix HGU133Plus2.0 platform (GPL570) (Affymetrix, Santa Clara, CA, USA). A total of seven prostate cancer data sets and 16 breast cancer data sets were identified and reviewed for meta-analysis. Meta-analysis of the correlation coefficients was performed using the library rmeta, and the R script is available at http://www. lerner.ccf.org/gmi/igac/published_data. Forest plots showing a summary estimate of the correlation between the expression of PTEN and AR in prostate cancer and breast cancer tumor tissue.
Cell culture and pharmacological treatments AR-positive prostate cancer cell lines LNCaP, CWR22rv1 and AR negative PC-3, DU145 cells were purchased from the ATCC (American Type Culture Collection, Manassas, VA, USA). LAPC4 cells were available in the laboratory of Dr Heston. AR-positive C4-2 cells (UroCor, Oklahoma City, OK, USA) belong to an androgen-independent subline, developed from LNCaP xenografts in castrated nude mice. Breast cancer cell lines MDA-MB-231, MDA-MB-453, MDA-MB-468, MCF-7 and BT-549 were purchased from ATCC. 4, 5a-Dihydrotestosterone (DHT) is from SigmaAldrich (St Louis, MO, USA; per Dr Silverman). Bicalutamide (Casodex) was purchased from Astra-Zeneca (Cheshire, UK RHS; per Dr Heston).
Patient mutation analysis
We utilized anonymized genomic DNA samples from CS/CSL patients (n ¼ 2399) archived in the Genomic Medicine Biorepository, Cleveland Clinic Genomic Medicine Institute, (Cleveland, OH, USA). Classic CS was diagnosed using the operational diagnostic criteria of the International Cowden Consortium (Liaw et al., 1997) . CSL defines a broad class of patients with combinations of features, but who do not meet the operational diagnostic criteria. We utilized genomic DNA from population controls (n ¼ 48). Informed consent was obtained for all subjects in accordance with procedures and protocols approved by the respective Human Subjects Protection Committee of each participating institution. Genomic DNA from patient whole blood was amplified by PCR and subjected to direct sequencing (ABI3730 Â l) of the PTEN promoter from À1344 to À745 region (Mutter et al., 2000) .
RNA inhibition
Control siRNA was a pool of four-scrambled non-specific siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Anti-AR siRNA (sc-29 204, Santa Cruz Biotechnology) contains a pool of four target-specific siRNAs with the following sequences: (A) 5 0 -CAGUCCCACUUGUGUCAAA-3 0 , (B) 5 0 -CCUGAUCUGUGGAGAUGAA-3 0 , (C) 5 0 -GUCGUCU UCGGAAAUGUUA-3 0 , (D) 5 0 -GACAGUGUCACACAUU GAA-3 0 .
Western blotting
Western blotting was performed as described elsewhere (Ghosh et al., 2005) . Mouse monoclonal anti-AR (441) and anti-Lamin-A antibodies were obtained from Santa Cruz Biotechnology. Mouse monoclonal anti-tubulin antibody was obtained from Sigma-Aldrich. Mouse monoclonal anti-PTEN antibody was obtained from Cascade Biosciences, (Portland, OR, USA).
Promoter activity assay AR transcriptional activity was measured by using the Cignal report assay kit (SA Bioscience, Frederick, MD, USA), according to the manufacturer's instructions. We generated PTEN promoters tagged with the firefly luciferase gene, as described in our previous study (Teresi et al., 2008) . Reporter gene activity was determined by dual luciferase assay using a luciferase enzyme assay system (Promega, Madison, WI, USA). P53-response-element reporter plasmid was obtained from Addgene (Cambridge, MA, USA).
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) qRT-PCR to quantitate PTEN mRNA expression was measured using SYBR Green (Applied Biosystem, Foster City, CA, USA), exactly according to the manufacturer's specifications. Expression of GAPDH was used as the internal control. The PTEN primer sequences are as follows: exon 3-4 Forward: 5 0 -ATATTCTCTGAAAAGCTCTGG-3 0 , Reverse: 5 0 -GACAGTAAGATACAGTCTATC-3 0 ; exon 4-5 Forward: 5 0 -CATTATAAAGATTCAGGCAATG-3 0 , Reverse: 5 0 -TCC AGGAAGAGGAAAGGAAA-3 0 ; exon 5-6 Forward: 5 0 -ACC TGTTAAGTTTGTATGCAA-3 0 ; Reverse: 5 0 -GATATGGTT AAGAAAACTGTTC-3 0 .
Chromatin Immunoprecipitation (ChIP) assay ChIP assays were performed with the EZ Chromatin Immunoprecipitation assay kit (EZ ChIP, Upstate Biotechnology, Charlottesville, VA), according to the manufacturer's protocol. An amount of 5 mg of antibody was used in every precipitation. The ChIP-eluted DNA was quantified by qRT-PCR, using primers specific for the full length and various regions of the PTEN promoter.
